The research aims to determine the most effective dose and timing of UA supplementation in vitro to induce prolonged growth of CD8+ T cells with enhanced anti-tumor properties, particularly in the context of adoptive T cell therapy (292). The gene discussed is CD8A; the disease is neoplasm.